Day One Biopharmaceuticals, Inc. (DAWN)
Automate Your Wheel Strategy on DAWN
With Tiblio's Option Bot, you can configure your own wheel strategy including DAWN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DAWN
- Rev/Share 1.5765
- Book/Share 4.6686
- PB 1.388
- Debt/Equity 0.0061
- CurrentRatio 10.6237
- ROIC -0.4391
- MktCap 656825760.0
- FreeCF/Share -1.611
- PFCF -3.9695
- PE -9.6347
- Debt/Assets 0.0055
- DivYield 0
- ROE -0.1498
- Rating B-
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Reiterated | DAWN | Needham | -- | Buy | $32 | $33 | Oct. 9, 2024 |
News
Day One Biopharmaceuticals, Inc. (DAWN) Q1 2025 Earnings Call Transcript
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Joey Perrone - Senior Vice President, Finance & Investor Relations Jeremy Bender - Chief Executive Officer Lauren Merendino - Chief Commercial Officer Charles York - Chief Operating & Financial Officer Elly Barry - Chief Medical Officer Conference Call Participants Tara Bancroft - TD Cowen Alec Stranahan - Bank of America Soumit Roy - Jones Research Andrea Newkirk - Goldman Sachs Andres Maldonado - H.C. Wainwright Operator Ladies and gentlemen, thank you for standby.
Read More
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates
Published: May 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Day One Biopharmaceuticals, Inc. (DAWN) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.72 per share a year ago.
Read More
Day One Biopharmaceuticals, Inc. (DAWN) Q4 2024 Earnings Call Transcript
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Neutral
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Joey Perrone - SVP, Finance and IR Jeremy Bender - CEO Lauren Merendino - CCO Charles York - COO and CFO Conference Call Participants Andrea Newkirk - Goldman Sachs Tara Bancroft - TD Cowen Joe Catanzaro - Piper Sandler Alec Stranahan - Bank of America Andres Maldonado - H.C. Wainwright Operator Hello, ladies and gentlemen, and welcome to the Day One Biopharmaceuticals Fourth Quarter and Full Year 2024 Financial and Operating Results Conference Call.
Read More
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Tops Revenue Estimates
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Negative
Day One Biopharmaceuticals, Inc. (DAWN) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.64 per share a year ago.
Read More
New Strong Buy Stocks for February 13th
Published: February 13, 2025 by: Zacks Investment Research
Sentiment: Positive
SYF, SSB, VCYT, DAWN and FISI have been added to the Zacks Rank #1 (Strong Buy) List on February 13, 2025.
Read More
About Day One Biopharmaceuticals, Inc. (DAWN)
- IPO Date 2021-05-27
- Website https://dayonebio.com
- Industry Biotechnology
- CEO Dr. Jeremy Bender M.B.A., Ph.D.
- Employees 181